Related Experiment Videos
Hepatic tissue engineering.
Katherine M Kulig1, Joseph P Vacanti
1Massachusetts General Hospital, Warren 11, 55 Fruit Street, Boston, MA 02114, USA.
Transplant Immunology
|May 26, 2004
Summary
Fulminant hepatic failure (FHF) necessitates advanced treatments like liver assist devices (LADs) and tissue engineering. Researchers are developing implantable livers using MEMs technology to address donor organ shortages.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Hepatology
Background:
- Fulminant hepatic failure (FHF) is a critical condition with high mortality in the US.
- Organ transplantation is the sole current solution, but donor organ scarcity limits availability.
- Liver Assist Devices (LADs) offer temporary support, bridging patients to transplantation.
Purpose of the Study:
- To explore advancements in hepatic tissue engineering for FHF treatment.
- To overcome challenges in scaffold selection, cell sourcing, and immunological compatibility.
- To develop a fully functioning, implantable artificial liver.
Main Methods:
- Utilizing bioreactors to enhance hepatocyte survival and viability.
- Incorporating growth factors and mitogens bound to polymer scaffolds for controlled release.
- Applying MicroElectroMechanical Systems (MEMs) technology to mimic liver vasculature.
Main Results:
- Bioreactors successfully sustained viable hepatocytes for several weeks.
- MEMs technology enabled the creation of a platform mimicking natural liver vasculature.
- The developed platform supports functional and viable hepatocytes.
Conclusions:
- Hepatic tissue engineering holds promise for reducing reliance on donor organs.
- Advancements in bioreactors, scaffold technology, and MEMs are crucial for developing artificial livers.
- This platform technology represents a significant step toward a fully implantable liver solution.